Beranda › Limfoma Sel-T › Wisconsin › Madison
Uji klinis Limfoma Sel-T di Madison, WI
3 studi untuk Limfoma Sel-T mencari peserta di lokasi sekitar Madison (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.
Teks studi resmi (Bahasa Inggris)
Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →
Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma
Menerima pesertaFase 2
- University of Wisconsin Carbone Cancer Center - Eastpark Medical Center, Madison
- University of Wisconsin Carbone Cancer Center - University Hospital, Madison
Soquelitinib vs Standard of Care in Participants With Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma
Menerima pesertaFase 3
- University of Wisconsin Carbone Cancer Center, Madison
Testing Whether High Dose Chemotherapy and Infusion of the Patients' Own Stem Cells Improves Survival in Patients With Peripheral T-cell Lymphoma Who Achieved a Complete Response at the End of the Initial Chemotherapy
Menerima pesertaFase 3
- University of Wisconsin Carbone Cancer Center - Eastpark Medical Center, Madison
- University of Wisconsin Carbone Cancer Center - University Hospital, Madison
Uji klinis Limfoma Sel-T di kota lain
- New York City, NY13 studi
- Philadelphia, PA10 studi
- Baldwin Park, CA9 studi
- Boston, MA9 studi
- Houston, TX8 studi
- Atlanta, GA8 studi
- Chicago, IL6 studi
- Seattle, WA6 studi
- Columbus, OH6 studi
- Rochester, MN6 studi
- New Haven, CT5 studi
- Miami, FL5 studi
Studi lain di Madison
- Kanker Prostat29 studi
- Kanker Kolorektal22 studi
- Kanker Payudara22 studi
- Kanker Metastatik21 studi
- Kanker Paru Non-Sel Kecil16 studi
- Leukemia Mieloid Akut16 studi
- Melanoma15 studi
- Kanker (semua jenis)14 studi
- Kanker Ovarium13 studi
- Kanker Lambung11 studi
- Kanker Paru10 studi
- Kanker Pankreas10 studi
Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.